Erdafitinib
Sign in to save this workspacePrimary targets: FGFR1 · FDA status: FDA Approved
Selectivity scorecard
KISS
95.71
Gini
0.737
CATDS
0.018
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Erdafitinib. Strongest target: FGFR3 at 99.1% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FGFR3 | 99.1% | 0.9% |
| 2 | FGFR2 | 99.0% | 1.0% |
| 3 | FGFR1 | 99.0% | 1.0% |
| 4 | FGFR4 | 98.0% | 2.0% |
| 5 | C_KIT | 98.0% | 2.0% |
| 6 | FLT4_VEGFR3 | 97.9% | 2.1% |
| 7 | LYN | 97.8% | 2.2% |
| 8 | FMS | 97.6% | 2.4% |
| 9 | EIF2AK2 | 97.0% | 3.0% |
| 10 | FLT1_VEGFR1 | 96.6% | 3.4% |
| 11 | DDR1 | 95.8% | 4.2% |
| 12 | RET | 94.7% | 5.3% |
| 13 | PDGFRA | 94.5% | 5.5% |
| 14 | DDR2 | 93.5% | 6.5% |
| 15 | KDR_VEGFR2 | 91.8% | 8.2% |
| 16 | LCK | 91.7% | 8.3% |
| 17 | ABL1 | 90.9% | 9.1% |
| 18 | EPHB4 | 89.7% | 10.3% |
| 19 | EPHB1 | 89.3% | 10.7% |
| 20 | EPHA5 | 87.6% | 12.4% |
Selectivity landscape
Where Erdafitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Erdafitinib.
Annotations
Sign in to read and post annotations.
Loading…